

Form PTO-1449 (modified)

Atty. Docket No.  
UTSC:594USD1/MBWSerial No.  
09/974,753

List of Patents and Publications for Applicant's

Applicant  
Alan J. SchroitCOPY OF PAPERS  
ORIGINALLY FILED

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
October 9, 2001Group:  
1642U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
W	A1	4,196,265	4/1/80	Koprowski <i>et al.</i>	435	70.21	8/11/78
W	A2	4,916,118	4/10/90	Fidler <i>et al.</i>	514	16	8/12/87
W	A3	4,916,448	4/10/90	Thor	340	970	2/26/88
W	A4	4,994,440	2/19/91	Creaven	514	8	2/13/89
W	A5	6,312,694 B1	11/6/01	Thorpe <i>et al.</i>	424	178.1	7/12/99

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
W	B1	JP 3197865	8/29/81	Japan			Abstract only

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W	C1	"New cancer metastasis inhibitory compsn. for both humans and animals - comprises peptide cpds. having cell adhesive activity and lipid(s) having 14-24C fatty acid residue, sphingoglycolipid and cholesterol residues," abstract of JP08225457, <i>Derwent Publications Ltd.</i> , #AN 96-450927, 1996
W	C2	"Remington's Pharmaceutical Sciences" 15 Edition, pages 1035-1038 and 1570 and 1580.
W	C3	Allen and Choun, "Large unilamellar liposomes with low uptake into the reticuloendothelial system," <i>FEBS Lett.</i> , 223:42-46, 1987.
W	C4	Alving, "Antibodies to liposomes, phospholipids and phosphate esters," <i>Chem. Phys. Lipids</i> , 40:303-314, 1986.
W	C5	Asherson and Cervera, "Antiphospholipid Syndrome," <i>J. Invest. Dermatol.</i> , 100(1):21S-27S, 1993.
W	C6	Balasubramanian and Schroit, "Characterization of Phosphatidylserine-dependent $\beta_2$ -Glycoprotein I Macrophage Interactions," <i>J. Biol. Chem.</i> , 273(44), pgs. 29272-29277, 1998.

25123897.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



RECEIVED  
MAR 12 2002

TECH CENTER 1600/2900

COPY OF PAPERS  
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.  
UTSC:594USD1/MPWSerial No.  
09/974,753COPY OF PAPERS  
ORIGINALLY FILED

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
October 9, 2001Group:  
1642U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
RECEIVED MAR 12 2002 TECH CENTER 1600/2900	C7	Baldwin <i>et al.</i> , "Surface exposure of phosphatidylserine is associated with the swelling and osmotically-induced fusion of human erythrocytes in the presence of Ca <sup>2+</sup> ," <i>Biochim. Biophys. Acta</i> , 1028:14-20, 1990.
	C8	Balet <i>et al.</i> , "1-Palmitoyl-2-thiopalmitoyl phosphatidylcholine, a highly specific chromogenic substrate of phospholipase A <sub>2</sub> ," <i>Biochem. Biophys. Res. Commun.</i> , 150:561-567, 1988.
	C9	Banerji and Alving, "Antibodies to liposomal phosphatidylserine and phosphatidic acid," <i>Biochem. Cell. Biol.</i> , 68:96-101, 1990.
	C10	Bate <i>et al.</i> , "Phospholipids coupled to a carrier induce IgG antibody that blocks tumour necrosis factor induction by toxic malaria antigens," <i>Immunol.</i> , 79:138-145, 1993.
	C11	Becker <i>et al.</i> , "Antiphospholipid syndrome associated with immunotherapy for patients with melanoma," <i>Cancer</i> , 73:1621-1624, 1994.
	C12	Bennett <i>et al.</i> , "Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine," <i>Circ. Res.</i> , 77:1136-1142, 1995.
	C13	Bevers <i>et al.</i> , "Changes in membrane phospholipid distribution during platelet activation," <i>Biochim. Biophys. Acta</i> , 736:57-66, 1983.
	C14	Bevers <i>et al.</i> , "Defective Ca <sup>2+</sup> -induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder: a study of the red blood cells of scott syndrome," <i>Blood</i> , 79:380-388, 1992.
	C15	Bevers <i>et al.</i> , "Generation of Prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets," <i>Eur. J. Biochem.</i> , 122:429-436, 1982.
	C16	Bruckheimer and Schroit, "Membrane phospholipid asymmetry: host response to the externalization of phosphatidylserine," <i>J. Leukocyte Biol.</i> , 59:784-788, 1996.
	C17	Brunner and Richards, "Analysis of membranes photolabeled with lipid analogues," <i>J. Biol. Chem.</i> , 255:3319-3329, 1980.
	C18	Comfurius <i>et al.</i> , "Enzymatic synthesis of phosphatidylserine on small scale by use of a one-phase system," <i>J. Lipid Res.</i> , 31:1719-1721, 1990.
	C19	Connor <i>et al.</i> , "Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: quantitative assessment of outer-leaflet lipid by prothrombinase complex formation," <i>Proc. Natl. Acad. Sci. USA</i> , 86:3184, 1989.

25123897.1

EXAMINER:

*Gary Blute*

DATE CONSIDERED:

3/19/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

COPY OF PAPERS  
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.  
UTSC:594USD1/MBWSerial No.  
09/974,753COPY OF PAPERS  
ORIGINALLY FILED

List of Patents and Publications for Applicant's

Applicant  
Alan J. Schroit

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
October 9, 2001Group:  
1642U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W	C20	Connor <i>et al.</i> , "Exposure of phosphatidylserine in the outer leaflet of human red blood cell." <i>Biol. Chem.</i> , 269:2399-2404, 1994.
W	C21	Couvreux <i>et al.</i> , "Nanocapsules: a new type of lysosomotropic carrier," <i>FEBS Lett.</i> , 84:323-326, 1977.
W	C22	Couvreux, "Polyalkylcyanoacrylates as colloidal drug carriers," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 5:1-20, 1988.
W	C23	Creaven <i>et al.</i> , "Initial Clinical Trial of Muramyl Tripeptide Derivative (MTP-PE) Encapsulated in Liposomes: an Interim Report," <i>UCLA Symp. Mol. Cell. Biol.</i> , New Ser 89: 297-303, 1989, Abstract Only.
W	C24	Devaux and Zachowski, "Maintenance and consequences of membrane phospholipid asymmetry," <i>Chem. Phys. Lipids</i> , 73:107, 1994.
W	C25	Devaux, "Static and dynamic lipid asymmetry in cell membranes," <i>Biochemistry</i> , 30:1163-1173, 1991.
W	C26	Diaz <i>et al.</i> , "Generation of phenotypically aged phosphatidylserine-expressing erythrocytes by dialauroylphosphatidylcholine-induced vesiculation," <i>Blood</i> , 87:2956-2961, 1996.
W	C27	Diaz <i>et al.</i> , "Synthesis of disulfide-containing phospholipid analogs for the preparation of head group-specific lipid antigens: generation of phosphatidylserine antibodies," <i>Bioconjugate Chem.</i> , 9:250-254, 1998.
W	C28	Etemadi, "Membrane asymmetry, a survey and critical appraisal of the methodology, II. methods for assessing the unequal distribution of lipids," <i>Biochim. Biophys. Acta</i> , 604:423-475, 1980.
W	C29	Fadok <i>et al.</i> , "Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages," <i>J. Immunol.</i> , 148:2207-2216, 1992.
W	C30	Gabizon and Papahadjopoulos, "Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors," <i>Proc. Natl. Acad. Sci. USA</i> , 85:6949-6953, 1988.
W	C31	Gaffet <i>et al.</i> , "Phosphatidylserine exposure on the platelet plasma membrane during A23187-induced activation is independent of cytoskeleton reorganization," <i>Eur. J. Cell Biol.</i> , 67:336-345, 1995.

25123897.1

EXAMINER:

DATE CONSIDERED:

3/14/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



TECH CENTER 1600/2900

RECEIVED  
MAR 12 2002

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:594USD1/MBW

09/974,753

COPY OF PAPERS  
ORIGINALLY FILED

List of Patents and Publications for Applicant's

Applicant

Alan J. Schroit

INFORMATION DISCLOSURE STATEMENT

Filing Date:

October 9, 2001

Group:

1642

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

COPY OF PAPERS  
ORIGINALLY FILED

Exam. Init.	Ref. Des.	Citation
W	C32	Galli <i>et al.</i> , "Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor," <i>Lancet</i> , 335:1544-1547, 1990.
W	C33	Gefter <i>et al.</i> , "Simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells," <i>Somat. Cell Genet.</i> , 3:231-236, 1977.
W	C34	Geldwerth <i>et al.</i> , "Transbilayer mobility and distribution of red cell phospholipids during storage," <i>J. Clin. Invest.</i> , 92:308-314, 1993.
W	C35	Ghosh and Bachhawat, "Targeting of Liposomes to Hepatocytes," <i>Targeted Diagn. Ther.</i> , 4:87-103, 1991.
W	C36	Goding, "Monoclonal Antibodies: Principles and Practice," pp. 60-74. 2nd Edition, Academic Press, Orlando, FL, 1986.
W	C37	Gordesky <i>et al.</i> , "The reaction of chemical probes with the erythrocyte membrane," <i>J. Membr. Biol.</i> , 20:111-132, 1975.
W	C38	Grasseti and Murray, "Determination of sulfhydryl groups with 2,2'- or 4,4'-dithiodipyridine," <i>Arch. Biochem. Biophys.</i> , 119:41-49, 1967.
.	C39	Gupta <i>et al.</i> , "Adjuvants for human vaccines—current status, problems and future prospects," <i>Vaccine</i> , 13(14):1263-1276, 1995
	C40	Henry-Michelland <i>et al.</i> , "Attachment of antibiotics to nanoparticles: preparation, drug release, and antimicrobial activity in vitro," <i>Int. J. Pharm.</i> , 35:121-127, 1987.
W	C41	Herrmann and Devaux, "Alteration of the aminophospholipid translocase activity during in vivo and artificial aging of human erythrocytes," <i>Biochim. Biophys. Acta</i> , 1027:41-46, 1990.
W	C42	Herstoff and Bogaars, "Cutaneous lupus erythematosus associated with melanoma and BCG vaccine therapy," <i>Arch. Dermatol.</i> , 115(7):856-859, 1979.
	C43	Janeway <i>et al.</i> , <i>Immunobiology</i> , Garland Publishing, page 1:32, 1994.
W	C44	Jue <i>et al.</i> , "Addition of sulfhydryl groups to <i>Escherichia coli</i> ribosomes by protein modification with 2-iminothiolane (methyl 4-mercaptobutyrimide)," <i>Biochemistry</i> , 17:5399-5405, 1978.
W	C45	Katsuragawa <i>et al.</i> , "Monoclonal antiphosphatidylserine antibody reactivity against human first-trimester placental trophoblasts," <i>Am. J. Obstet. Gynecol.</i> , 172:1592-1597, 1995.


25123897.1

EXAMINER:

DATE CONSIDERED:

3/19/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



TECH CENTER 1600/2900

Form PTO-1449 (modified)

Atty. Docket No.  
UTSC:594USD1/MBWSerial No.  
09/974,753COPY OF PAPERS  
ORIGINALLY FILED

List of Patents and Publications for Applicant's

Applicant  
Alan J. Schroit

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
October 9, 2001Group:  
1642U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

COPY OF PAPERS  
ORIGINALLY FILED

Exam. Init.	Ref. Des.	Citation
aw	C46	Killion and Baker, "Autoreactive factors identify tumor-host heterogeneity and responsiveness to immunotherapy," <i>Cancer Immunol Immunother.</i> , 12:111-117, 1982.
aw	C47	Kohler and Milstein, "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," <i>Eur. J. Immunol.</i> , 6:511-519, 1976.
aw	C48	Kuypers <i>et al.</i> , "Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V," <i>Blood</i> , 87:1179-1187, 1996.
aw	C49	Mackworth-Young, "Antiphospholipid antibodies: more than just a disease marker?," <i>Immunol. Today</i> , 11(2):60-65, 1990.
aw	C50	Maneta-Peyret <i>et al.</i> , "Demonstration of high specificity antibodies against phosphatidylserine," <i>J. Immun. Met.</i> , 108:123-127, 1988.
aw	C51	Maneta-Peyret <i>et al.</i> , "Demonstration that anti-phospholipid auto-antibodies react with both anionic d zwitterionic phospholipids," <i>Immunol. Lett.</i> , 35:141-146, 1993.
aw	C52	Maneta-Peyret <i>et al.</i> , "Specific immunocytochemical visualization of phosphatidylserine," <i>J. Immunol. Meth.</i> , 122:155-159, 1989.
aw	C53	McNeil <i>et al.</i> , "Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: $\beta_2$ -glycoprotein I (apolipoprotein H)," <i>Proc. Natl. Acad. Sci. USA</i> , 87:4120-4124, 1990.
aw	C54	Menon, "Flippases," <i>Trends Cell Biol.</i> , 5:355, 1995.
aw	C55	Mizushima and Igarashi, "Studies on polypeptide drug delivery systems: tissue distribution of immunoglobulin G conjugated with lecithin," <i>J. of Controlled Release</i> , 17:99-104, 1991.
aw	C56	Moestrup <i>et al.</i> , " $\beta_2$ -Glycoprotein-I (Apolipoprotein H) and $\beta_2$ -Glycoprotein-I-Phospholipid Complex Harbor a Recognition Site for the Endocytic Receptor Megalin," <i>J. Clin. Invest.</i> , 102(5), pgs. 902-909, 1998
aw	C57	Naldi <i>et al.</i> , "Antiphospholipid antibodies and melanoma: a link?," <i>Dermatology</i> , 184(2):156, 1992.
aw	C58	Nelson, "Autoantibodies in cancer patients," <i>Pathology</i> , 9(2):155-160, 1977.

25123897.1


EXAMINER:

DATE CONSIDERED:

3/9/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



TECH CENTER 1600/2900

MAR 12 2002  
RECEIVED

Form PTO-1449 (modified)

Atty. Docket No.  
UTSC:594USD1/MBWSerial No.  
09/974,753COPY OF PAPERS  
ORIGINALLY FILED

List of Patents and Publications for Applicant's

Applicant  
Alan J. Schroit

INFORMATION DISCLOSURE STATEMENT

Filing Date:  
October 9, 2001Group:  
1642

(Use several sheets if necessary)

U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W	C59	OoSting <i>et al.</i> , "Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein c, or protein s: an explanation for their pathogenic mechanism," <i>Blood</i> , 81:2618-2625, 1993.
W	C60	Pierotti and Colnaghi, "Natural antibodies directed against murine lymphosarcoma cells," <i>J. Natl. Cancer Inst.</i> , 55(4):945-949, 1975.
W	C61	Poltz and Kostner, "The binding of $\beta_2$ -glycoprotein-I to human serum lipoproteins," <i>FEBS Lett.</i> , 102:183-186, 1979.
W	C62	Rauch and Janoff, "Phospholipid in the hexagonal II phase is immunogenic: evidence for immunorecognition of nonbilayer lipid phases <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 87:4112-4114, 1990.
W	C63	Rauch <i>et al.</i> , "Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems," <i>J. Biol. Chem.</i> , 262:9672-9677, 1986.
W	C64	Regen, "Polymerized-depolymerized vesicles. A reversible phosphatidylcholine-based membrane," <i>J. Am. Chem. Soc.</i> , 105:6354-6355, 1983.
W	C65	Riddles <i>et al.</i> , "Reassessment of ellman's reagent," <i>Meth. Enzymol.</i> , 91:49-60, 1983.
W	C66	Rosenberg and Rogentine, "Natural human antibodies to "hidden" membrane components," <i>Nature</i> , 239:203, 1972.
W	C67	Rosing <i>et al.</i> , "The role of activated human platelets in prothrombin and factor x activation," <i>Blood</i> , 65:319-322, 1985.
W	C68	Rosing <i>et al.</i> , "The role of phospholipids and factor V <sub>a</sub> in the prothrombinase complex," <i>J. Biol. Chem.</i> , 255:274-283, 1980.
W	C69	Rote <i>et al.</i> , "Expression of phosphatidylserine-dependent antigens on the surface of differentiating BeWo human choriocarcinoma cells," <i>Am. J. Rep. Immunol.</i> , 33:114-121, 1995.
W	C70	Rote <i>et al.</i> , "Immunologic detection of phosphatidylserine externalization during thrombin-induced platelet activation," <i>Clin. Immunol. Immunopathol.</i> , 66:193-200, 1993.
W	C71	Roubey, "Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies," <i>Blood</i> , 84:2854-2867, 1994.

25123897.1

EXAMINER:

DATE CONSIDERED:

3/19/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

TECH CENTER 1600/2900

COPY OF PAPERS  
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:594USD1/MBW

Serial No.

09/974,753

COPY OF PAPERS  
ORIGINALLY FILED

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 9, 2001

Group:

1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>aw</i>	C72	Sambrano and Steinberg, "Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidylserine," <i>Proc. Natl. Acad. Sci. USA</i> , 92:1396-1400, 1995.
<i>aw</i>	C73	Samuel <i>et al.</i> , "Polymerized-depolymerized vesicles. Reversible thiol-disulfide-based phosphatidylcholine membrane," <i>J. Am. Chem. Soc.</i> , 107:42-47, 1985.
<i>aw</i>	C74	Schick <i>et al.</i> , "Location of phosphatidylethanolamine and phosphatidylserine in the human platelet plasma membrane," <i>J. Clin. Invest.</i> , 57:1221-1226, 1976.
<i>aw</i>	C75	Schousboe, "Purification, characterization and identification of an agglutinin in human serum," <i>Biochim. Biophys. Acta</i> , 579:396-408, 1979.
<i>aw</i>	C76	Schroit and Madsen, "Synthesis and properties of radioiodinated phospholipid analogues that spontaneously undergo vesicle-vesicle and vesicle-cell transfer," <i>Biochemistry</i> , 22:3617-3623, 1983.
<i>aw</i>	C77	Schroit and Zwaal, "Transbilayer movement of phospholipids in red cell and platelet membranes," <i>Biochim. Biophys. Acta</i> , 1071:313-329, 1991.
<i>aw</i>	C78	Sims <i>et al.</i> , "Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane," <i>J. Biol. Chem.</i> , 264:17049-17057, 1989.
<i>aw</i>	C79	Tait and Gibson, "Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding," <i>J. Lab. Clin. Med.</i> , 123:741-748, 1994.
<i>aw</i>	C80	Tamamura <i>et al.</i> , "The immunological relations between acidic phospholipids and their antibodies," <i>Jpn. J. Exp. Med.</i> , 41:31-38, 1971.
	C81	Tannock <i>et al.</i> , <i>The Basic Science of Oncology</i> , 2 <sup>nd</sup> Edition, page 247, 1 <sup>st</sup> column, 1992.
<i>aw</i>	C82	Thiagarajan and Tait, "Binding of annexin V/Placental anticoagulant protein I to platelets," <i>J. Biol. Chem.</i> , 265:17420-17423, 1990.
<i>aw</i>	C83	Umeda, "Effective production of monoclonal antibodies against phosphatidylserine: stereo-specific recognition of phosphatidylserine by monoclonal antibody," <i>Immunol.</i> , 143:2273-2279, 1989.
<i>aw</i>	C84	Utsugi <i>et al.</i> , "Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes," <i>Cancer Res.</i> , 51(11):3062-3066, 1991.

25123897.1

EXAMINER:

DATE CONSIDERED:

3/19/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



TECH CENTER 1600/2900

COPY OF PAPERS  
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:594USD1/MBW

Serial No.

09/974,753

COPY OF PAPERS  
ORIGINALLY FILED

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Alan J. Schroit

Filing Date:

October 9, 2001

Group:

1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

COPY OF PAPERS  
ORIGINALLY FILED

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>W</i>	C85	Van Dieijen <i>et al.</i> , "The role of phospholipid and factor VIII <sub>a</sub> in the activation of bovine factor x," <i>J. Biol. Chem.</i> , 256:3433-3442, 1981.
<i>W</i>	C86	Verhoven <i>et al.</i> , "Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic t lymphocytes," <i>J. Exp. Med.</i> , 182:1597-1601, 1995.
<i>W</i>	C87	Verkleij <i>et al.</i> , "The asymmetric distribution of phospholipids in the human red cell membrane, a combined study using phospholipases and freeze-etch electron microscopy," <i>Biochim. Biophys. Acta</i> , 323(2):178-193, 1973.
<i>W</i>	C88	Vermes <i>et al.</i> , "A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin v," <i>J. Immunol. Meth.</i> , 184:39-51, 1995.
<i>W</i>	C89	Wurm, "β <sub>2</sub> -glycoprotein-I (apolipoprotein h) interactions with phospholipid vesicles," <i>Int. J. Biochem.</i> , 16:511-515, 1984.
<i>W</i>	C90	Zwaal and Schroit, "Pathophysiologic implications of membrane phospholipid asymmetry in blood cells," <i>Blood</i> , 89:1121-1132, 1997.
<i>W</i>	C91	Zwaal <i>et al.</i> , "Organization of phospholipids in human red cell membranes as detected by the action of various purified phospholipases," <i>Biochim. Biophys. Acta</i> , 406(1):83-96, 1975.

25123897.1

EXAMINER:

DATE CONSIDERED:

3/19/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



TECH CENTER 1600/2900

RECEIVED  
MAR 12 2002